Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
|Videos|April 29, 2011
Ted Okon Talks About the Issues With Reimbursement
Author(s)Ted Okon
Ted Okon Talks About the Issues With Reimbursement
Advertisement
Ted Okon the Executive Director of the Community Oncology Alliance (COA) Talks About the Issues With Reimbursement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5